N-hydroxy-3-[1-[4-[1-(2-piperidin-1-ylethyl)triazol-4-yl]phenyl]sulfonylpyrrol-3-yl]prop-2-enamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-hydroxy-3-[1-[4-[1-(2-piperidin-1-ylethyl)triazol-4-yl]phenyl]sulfonylpyrrol-3-yl]prop-2-enamide
• 化学式: C₂₂H₂₆N₆O₄S
• 分子量: 470.5
• InChiKey: ONANMLBKKJAIPO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  33
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  131
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• N-Sulphonylpyrroles and Their Use as Histone Deacetylase Inhibitors
  申请人：Maier Thomas

  公开号：US20080176848A1

  公开（公告）日：2008-07-24

  Compounds of a certain formula (I) in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, are novel effective HDAC inhibitors.

  具有特定化学式（I）的化合物，其中R1、R2、R3、R4、R5、R6和R7具有描述中指示的含义，是新颖有效的HDAC抑制剂。
• N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS
  申请人：MAIER Thomas

  公开号：US20100074862A1

  公开（公告）日：2010-03-25

  Compounds of a certain formula (I), in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, are novel effective HDAC inhibitors.

  具有某种公式（I）的化合物，其中R1、R2、R3、R4、R5、R6和R7具有描述中指示的含义，是新颖的有效HDAC抑制剂。
• HDAC INHIBITOR IN COMBINATION WITH IMMUNE CHECKPOINT MODULATOR FOR CANCER THERAPY
  申请人：4SC AG

  公开号：US20200261418A1

  公开（公告）日：2020-08-20

  The invention relates to methods, compositions and uses for the of treatment of cancer comprising the administration of an HDAC inhibitor as defined herein for the treatment of cancer in combination with at least one immune checkpoint modulator as defined herein.
• Combination comprising HDAC inhibitor and CD137 agonist for cancer therapy
  申请人：4SC AG

  公开号：US20210113528A1

  公开（公告）日：2021-04-22

  The invention relates to medical uses of an HDAC inhibitor of the below general formula I, wherein R1 to R7 are as described herein, or a salt or solvate thereof in combination with a CD137 agonist for the treatment of cancer.
• PHARMACEUTICAL COMBINATION PRODUCTS COMPRISING A HISTONE DEACETYLASE (HDAC) INHIBITOR AND A TLR7 AGONIST AND/OR TLR8 AGONIST FOR THE TREATMENT OF CANCER
  申请人：4SC AG

  公开号：US20210145799A1

  公开（公告）日：2021-05-20

  The invention relates to pharmaceutical combination products comprising an HD AC inhibitor, e.g. (E)-N-(2-amino-phenyl)-3-1-[4-(1-methyl-1H-pyrazol-4-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide as well as salts and or solvents thereof and TLR7 agonist and/or TLR8 agonist for the treatment of cancer. The present invention also relates to methods of treatment of patients suffering from cancer with these pharmaceutical combination products.